Loading...
Loading...
Promising ZEVALIN data reported in patients with diffuse large B-cell lymphoma (DLBCL); data suggest reduced need for standard chemotherapy.
ZEVALIN poster presentations also show positive results in diverse patient populations, including those receiving stem cell transplants and the elderly
Belinostat therapy shows encouraging activity in combination with chemotherapy regimen against aggressive form of lymphoma
Spectrum Pharmaceuticals
SPPI today announced promising clinical data in five poster presentations for ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, as well as a poster presentation and one e-abstract publication for belinostat, at the American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois, from June 1-5, 2012.
ZEVALIN – Promising clinical findings in DLBCL, including in elderly patients; ZEVALIN further associated with reduced need for chemotherapy
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in